Influence of iron status in the response to the deferoxamine test.
The study presented here was carried out to evaluate the possible relationship between serum iron and iron transferrin saturation with the response to the deferoxamine test in 86 chronic renal failure patients undergoing hemodialysis. The deferoxamine test was performed as a diagnostic tool for aluminum intoxication. Basal serum aluminum levels correlated with: (1) serum aluminum levels after the infusion of deferoxamine (r = 0.45; P < 0.05); (2) serum iron levels (r = -0.26; P < 0.05), and; (3) iron transferrin saturation (r = -0.33; P < 0.05). The increase in serum aluminum levels after deferoxamine administration (DAI) showed a negative relationship with serum iron levels (r = -0.23; P < 0.05) and iron transferrin saturation (r = -0.26; P < 0.05). The correlations improved when analysis of this study included only those patients with high serum iron levels or high iron transferrin saturation (r = -0.55). Patients with low probability of having aluminum overload (serum iron levels < 40 micrograms/L and DAI < 150 micrograms/L) had significantly higher values of serum iron, iron transferrin saturation, and serum ferritin levels compared with those patients with a high probability of having aluminum overload (serum aluminum levels > 40 micrograms/L and DAI > 150 micrograms/L). The study presented here suggests that patients who have indicators of iron repletion would tend to have lower increases in serum aluminum levels after the challenge with deferoxamine and presumably a higher incidence of false negative results with the deferoxamine test. These findings indicate that iron measurements must be always taken into account when interpreting the deferoxamine test.
Cannata
J B
JB
Instituto Reina Sofía de Investigación Nefrológica, Universidad de Oviedo, Spain.
Fernández-Martín
J L
JL
Díaz-López
B
B
Alonso
M
M
Olaizola
I
I
Acuña
G
G
Caramelo
C
C
Alvarez-Grande
J
J
D000535:Aluminum / Q000506:poisoning; D000931:Antidotes; D003676:Deferoxamine; D006801:Humans; D007501:Iron / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000175:diagnosis / Q000209:etiology; D012189:Retrospective Studies; D014168:Transferrin / Q000378:metabolism*
D000931:Antidotes; D014168:Transferrin; D000535:Aluminum; D007501:Iron; D003676:Deferoxamine